Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SCN4A | P35499 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6204990 | 0.98 | HSD17B3 (0.33) | HSD17B10TSHRMAPTHSD17B3POLB | |
| SCHEMBL5655529 | 0.84 | MEN1 (0.33) | HSD17B10TSHRMAPTPOLBCYP3A4 | |
| SCHEMBL29816130 | 0.84 | MAOA (0.35) | HSD17B10TSHRMAPTHSD17B3BLM | |
| SCHEMBL980578 | 0.84 | MAOA (0.35) | HSD17B10TSHRMAPTHSD17B3BLM | |
| SCHEMBL27719045 | 0.82 | HSD17B3 (0.33) | HSD17B10MAPTHSD17B3ALOX15BRPF1 | |
| Hydrochloric Acid SCHEMBL27489771 | 0.82 | BLM (0.34) | HSD17B10TSHRMAPTHSD17B3BLM | |
| Hydrochloric Acid SCHEMBL3719374 | 0.82 | BLM (0.34) | HSD17B10TSHRMAPTHSD17B3BLM | |
| SCHEMBL28390255 | 0.82 | HSD17B3 (0.40) | HSD17B10MAPTHSD17B3ALOX15BRPF1 | |
| SCHEMBL30366037 | 0.82 | HSD17B3 (0.40) | HSD17B10MAPTHSD17B3ALOX15BRPF1 | |
| SCHEMBL5695892 | 0.81 | P2RX7 (0.34) | MAPTCYP3A4CYP2C19TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-07 | — | — | US | claimed |
| EP-4661870-A1 | COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-12-17 | — | — | EP | claimed |
| WO-2024165470-A1 | COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-15 | — | — | WO | claimed |
| US-20230148194-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-11 | — | — | US | claimed |
| EP-4065574-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | Bayer Aktiengesellschaft (DE) | 2022-10-05 | — | — | EP | claimed |
| CN-106467541-B | Substituted quinolone analog derivative or its pharmaceutically acceptable salt or stereoisomer and its Pharmaceutical composition and application | 暨南大学 | 2019-04-05 | — | — | CN | claimed |
| CN-108948014-A | 1- aryl -4- Oxy-1, the preparation and application of the pyrido heterocycle compound of 4- dihydroquinoline structure | 江西科技师范大学 | 2018-12-07 | — | — | CN | claimed |
| US-20180312496-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORP (FI) | 2018-11-01 | — | — | US | claimed |
| WO-2016181414-A1 | PROCESS FOR THE SYNTHESIS OF IVACAFTOR AND RELATED COMPOUNDS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-11-17 | — | — | WO | claimed |
| EP-2697201-A2 | N-ETHYL-4-HYDROXYL-1-METHYL-5-(METHYL(2,3,4,5,6-PENTAHYDROXYHEXYL) AMINO)-2-OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE | Teva Pharmaceutical Industries Ltd. (IL) | 2014-02-19 | — | — | EP | claimed |
| WO-2013169746-A2 | N-ETHYL-4-HYDROXYL-1-METHYL-5-(METHYL(2,3,4,5,6-PENTAHYDROXYHEXYL) AMINO)-2-OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2013-11-14 | — | — | WO | claimed |
| CN-102984939-A | Deuterated N-ethyl-N-phenyl-1, 2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof | TEVA PHARMA | 2013-03-20 | — | — | CN | claimed |
| EP-2509954-A1 | 4 -OXO- 1H -QUINOLINE- 3 - CARBOXAMIDES AS MODULATORS OF ATP -BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2012-10-17 | — | — | EP | claimed |
| WO-2012098070-A1 | QUINOLINE DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | claimed |
| WO-2011072241-A9 | 4-OXO-1H-QUINOLINE-3-CARBOXAMIDES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-14 | — | — | WO | claimed |
| WO-2011072241-A1 | 4 -OXO- IH -QUINOLINE- 3 - CARBOXAMIDES AS MODULATORS OF ATP -BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-16 | — | — | WO | claimed |
| WO-2010073078-A2 | HETEROCYCLIC COMPOUNDS AS HDAC INHIBITORS | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2010-07-01 | — | — | WO | claimed |
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-07 | — | — | US | disclosed |
| CN-1081671-A | Use known medicine treatment diabetes | KABI PHARMACIA AB (SE) | 1994-02-09 | — | — | CN | disclosed |
| WO-1993019756-A1 | THE USE OF QUINOLINE-3-CARBOXAMIDE COMPOUNDS FOR TREATMENT OF DIABETES | KABI PHARMACIA AB (SE) | 1993-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | ZC3HAV1, CCR1, CCR6 | HSD17B10 2339/4885TSHR 2194/4885MAPT 4593/4885 |
| US-20180312496-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD1, BRD4, BRD2 | HSD17B10 1828/4885TSHR 1561/4885MAPT 2619/4885 |
| US-20230148194-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | DGKK, DGKG, DGKA | HSD17B10 3531/4885TSHR 3319/4885MAPT 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.